suPAR and chronic kidney disease: a podocyte story
The soluble urokinase-type plasminogen activator receptor (suPAR) is a circulating signaling molecule derived from immature myeloid cells. Elevated levels of suPAR have been linked to the pathogenesis of the kidney disease focal and segmental glomerulosclerosis. Here, suPAR acts on podocytes by acti...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
08 July 2017
|
| In: |
Pflügers Archiv
Year: 2017, Volume: 469, Issue: 7-8, Pages: 1017-1020 |
| ISSN: | 1432-2013 |
| DOI: | 10.1007/s00424-017-2026-7 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.1007/s00424-017-2026-7 Verlag, Volltext: https://link.springer.com/article/10.1007/s00424-017-2026-7 
|
| Author Notes: | Martin Zeier, Jochen Reiser |
| Summary: | The soluble urokinase-type plasminogen activator receptor (suPAR) is a circulating signaling molecule derived from immature myeloid cells. Elevated levels of suPAR have been linked to the pathogenesis of the kidney disease focal and segmental glomerulosclerosis. Here, suPAR acts on podocytes by activating αvβ3 integrins. Large observational studies showed that suPAR also predicts chronic kidney disease incidence and progression by predating the disease by several years prior to any other known marker of renal dysfunction. suPAR is rapidly developing into a prime target for pharmacotherapy as its neutralization is forecasted to be feasible and safe. |
|---|---|
| Item Description: | First online: 08 July 2017 Gesehen am 03.07.2018 |
| Physical Description: | Online Resource |
| ISSN: | 1432-2013 |
| DOI: | 10.1007/s00424-017-2026-7 |